AIM: To assessed the clinical significance of protocol liver biopsy (PLB) in pediatric liver transplantation (LT). METHODS: Between July 2008 and August 2012, 89 and 55 PLBs were performed in pediatric patients at two and five years after LT, respectively. We assessed the histopathological findings using the Metavir scoring system, including activity (A) and fibrosis (F), and we identified factors associated with scores of ≥ A1 and ≥ F1. Our results clarified the timing and effectiveness of PLB. RESULTS: The incidences of scores of ≥ A1 and ≥ F1 were 24.7% and 24.7%, respectively, at two years after LT and 42.3% and 34.5%, respectively, at five years. Independent risk factors in a multivariate analysis of a score of ≥ A1 at two years included ≥ 2 h of cold ischemic time, no acute cellular rejection and an alanine amino transaminase (ALT) level of ≥ 20 IU/L (P = 0.028, P = 0.033 and P = 0.012, respectively); however, no risk factors were identified for a score of ≥ F1. Furthermore, no independent risk factors associated with scores of ≥ A1 and ≥ F1 at five years were identified using multivariate analysis. A ROC curve analysis of ALT at two years for a score of ≥ A1 demonstrated the recommended cutoff value for diagnosing ≥ A1 histology to be 20 IU/L. The incidence of scores of ≥ A2 or ≥ F2 at two years after LT was 3.4% (three cases), and all patients had an absolute score of ≥ A2. In contrast to that observed for PLBs at five years after LT, the incidence of scores of ≥ A2 or ≥ F2 was 20.0% (11 cases), and all patients had an absolute score of ≥ F2. In all cases, the dose of immunosuppressants was increased after the PLB, and all ten patients who underwent a follow-up liver biopsy improved to scores of ≤ A1 or F1. CONCLUSION: PLB at two years after LT is an unnecessary examination, because the serum ALT level reflects portal inflammation. In addition, immunosuppressive therapy should be modulated to maintain the ALT concentration at a level less than 20 IU/L. PLB at five years is an excellent examination for the detection of early reversible graft fibrosis because no serum markers reflect this finding.
AIM: To assessed the clinical significance of protocol liver biopsy (PLB) in pediatric liver transplantation (LT). METHODS: Between July 2008 and August 2012, 89 and 55 PLBs were performed in pediatric patients at two and five years after LT, respectively. We assessed the histopathological findings using the Metavir scoring system, including activity (A) and fibrosis (F), and we identified factors associated with scores of ≥ A1 and ≥ F1. Our results clarified the timing and effectiveness of PLB. RESULTS: The incidences of scores of ≥ A1 and ≥ F1 were 24.7% and 24.7%, respectively, at two years after LT and 42.3% and 34.5%, respectively, at five years. Independent risk factors in a multivariate analysis of a score of ≥ A1 at two years included ≥ 2 h of cold ischemic time, no acute cellular rejection and an alanine amino transaminase (ALT) level of ≥ 20 IU/L (P = 0.028, P = 0.033 and P = 0.012, respectively); however, no risk factors were identified for a score of ≥ F1. Furthermore, no independent risk factors associated with scores of ≥ A1 and ≥ F1 at five years were identified using multivariate analysis. A ROC curve analysis of ALT at two years for a score of ≥ A1 demonstrated the recommended cutoff value for diagnosing ≥ A1 histology to be 20 IU/L. The incidence of scores of ≥ A2 or ≥ F2 at two years after LT was 3.4% (three cases), and all patients had an absolute score of ≥ A2. In contrast to that observed for PLBs at five years after LT, the incidence of scores of ≥ A2 or ≥ F2 was 20.0% (11 cases), and all patients had an absolute score of ≥ F2. In all cases, the dose of immunosuppressants was increased after the PLB, and all ten patients who underwent a follow-up liver biopsy improved to scores of ≤ A1 or F1. CONCLUSION: PLB at two years after LT is an unnecessary examination, because the serum ALT level reflects portal inflammation. In addition, immunosuppressive therapy should be modulated to maintain the ALT concentration at a level less than 20 IU/L. PLB at five years is an excellent examination for the detection of early reversible graft fibrosis because no serum markers reflect this finding.
Authors: Anthony J Demetris; Oyedele Adeyi; Chris O C Bellamy; Andrew Clouston; Frederic Charlotte; Albert Czaja; Ierachmiel Daskal; Magda S El-Monayeri; Paulo Fontes; John Fung; Bruno Gridelli; Maria Guido; Hironori Haga; John Hart; Eva Honsova; Stefan Hubscher; Tomoo Itoh; Nirag Jhala; Patricia Jungmann; Urmila Khettry; Charles Lassman; Saverio Ligato; John G Lunz; Amadeo Marcos; Marta Ida Minervini; Johan Mölne; Mike Nalesnik; Imad Nasser; Desley Neil; Erin Ochoa; Orit Pappo; Parmjeet Randhawa; Finn P Reinholt; Phil Ruiz; Mylène Sebagh; Marco Spada; Aurelio Sonzogni; Athanassios C Tsamandas; Annika Wernerson; Tong Wu; Funda Yilmaz Journal: Hepatology Date: 2006-08 Impact factor: 17.425
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: G Junge; R Neuhaus; L Schewior; J Klupp; O Guckelberger; J M Langrehr; S Tullius; P Neuhaus Journal: Transplant Proc Date: 2005-05 Impact factor: 1.066
Authors: C Venturi; C Sempoux; J Bueno; J C Ferreres Pinas; C Bourdeaux; J Abarca-Quinones; J Rahier; R Reding Journal: Am J Transplant Date: 2012-08-06 Impact factor: 8.086
Authors: Michael A Wallot; Michael Mathot; Magda Janssen; Tanja Hölter; Kilic Paul; Jean Paul Buts; Raymond Reding; Jean Bernard Otte; Etienne M Sokal Journal: Liver Transpl Date: 2002-07 Impact factor: 5.799
Authors: Sandy Feng; Anthony J Demetris; Katharine M Spain; Sai Kanaparthi; Bryna E Burrell; Udeme D Ekong; Estella M Alonso; Philip Rosenthal; Laurence A Turka; David Ikle; Nadia K Tchao Journal: Hepatology Date: 2016-07-27 Impact factor: 17.425
Authors: Josh Levitsky; David Goldberg; Abigail R Smith; Sarah A Mansfield; Brenda W Gillespie; Robert M Merion; Anna S F Lok; Gary Levy; Laura Kulik; Michael Abecassis; Abraham Shaked Journal: Clin Gastroenterol Hepatol Date: 2016-08-25 Impact factor: 11.382